For kidney transplant recipients, immunosuppression commonly consists of combination
treatment with a calcineurin inhibitor, an antiproliferative agent and a corticosteroid. Many …

In the US, approximately 35% of adults with systemic lupus erythematosus (SLE) have
clinical evidence of nephritis at the time of diagnosis, with an estimated total of 50–60 …

Background: Lupus nephritis (LN) is a common and severe organ involvement manifesting
itself in systemic lupus erythematosus (SLE). There is a considerable difference in …

Advances in maintenance immunosuppression over the past three decades have improved
solid organ transplantation outcomes dramatically. Uninterrupted access to …

Lupus nephritis (LN) is a common and important manifestation of systemic lupus
erythematosus (SLE). Evidence suggests higher rates of lupus renal involvement in A sian …

Lupus nephritis (LN) is a common and important manifestation of systemic lupus
erythematosus (SLE). Evidence suggests higher rates of lupus renal involvement in Asian …

Background. Two open-label studies demonstrated that conversion from mycophenolate
mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) significantly reduces …

Background. In renal transplant (RT) recipients, treatment with enteric-coated
mycophenolate sodium (EC-MPS) improves gastrointestinal (GI) tolerability compared with …

Background. Although enteric-coated mycophenolate sodium (EC-MPS) was developed to
reduce gastrointestinal (GI) side effects in kidney transplantation, a multicenter clinical trial of …

Candida albicans and Aspergillus species had accounted for the overwhelming majority of
opportunistic invasive fungal infections in hematopoietic stem cell transplantation (HSCT) …